MR and Inflammation After Preeclampsia
Key facts
- Who runs it
- Anna Stanhewicz, PhD
- Where
- Iowa City, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Early phase 1
- Started
- 17 Dec 2025
- Expected to end
- 1 Feb 2029
- Type of study
- Interventional
- Treatments tested
- Eplerenone
- Record updated
- 29 October 2026
- Why it stopped
- Trainee project; study never initiated
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- women who had preeclampsia and women who did not have preeclampsia
- 12 weeks to 5 years postpartum
- 18-45 years old
Who cannot take part
- current antihypertensive medication
- statin or other cholesterol-lowering medication
- history of hypertension or metabolic disease before pregnancy
- history of gestational diabetes
- history of gestational hypertension without preeclampsia
- skin diseases
- allergy to materials used during the experiment.(e.g. latex),
- known allergy to study drugs or salt-supplement
- current tobacco use
- currently pregnant
- body mass index less than 18.5 kg/m2
Where in United States
- University of IowaIowa City, United States
About the trial
What the trial wants to find out
The purpose of this investigation is to examine the role of inappropriate mineralocorticoid receptor activation in endothelial dysfunction and vascular inflammation in otherwise healthy women with a history of preeclampsia. The main questions it aims to answer are:
Read full original descriptionShow less
1. Does overactivation of the mineralocorticoid receptor contribute to reduced endothelial function in women who had preeclampsia? 2. To what extent does the mineralocorticoid receptor mediated exaggerated production of inflammatory cytokines in immune cells from women who had preeclampsia?
Participants will visit the research laboratory for 2 experimental visits:
* Visit 1: Skin blood flow will be measured using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) to examine blood vessels in a nickel-sized area of the skin. * Visit 2: Endothelial cells will be collected from an antecubital vein.
The group in the trial
- Assessment of microvascular functionTreatment being tested
The investigators use intradermal microdialysis to deliver eplerenone and L-NAME to the cutaneous microvasculature
Treatment: Eplerenone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Contribution of Mineralocorticoid Receptor Signaling to Vascular Dysfunction & Aberrant Inflammation After Preeclampsia
- Record updated
- 29 October 2026